MediGene (ETR:MDG1) has been assigned a €11.00 ($12.79) price target by equities researchers at Baader Bank in a research note issued to investors on Wednesday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the stock. Baader Bank’s target price indicates a potential upside of 90.31% from the stock’s previous close.
ETR:MDG1 traded up €0.02 ($0.02) during trading hours on Wednesday, hitting €5.78 ($6.72). 47,700 shares of the company traded hands, compared to its average volume of 306,207. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 6.05. The firm’s 50-day simple moving average is €5.89 and its 200-day simple moving average is €6.95. MediGene has a one year low of €5.32 ($6.19) and a one year high of €11.30 ($13.14). The company has a market cap of $141.94 million and a PE ratio of -6.05.
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Recommended Story: What are no-load funds?
Receive News & Ratings for MediGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene and related companies with MarketBeat.com's FREE daily email newsletter.